Immuron Ltd has released a press release.
US Defense Reports Immuron Travelan Targets Cholera
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Immuron
- Appendix 4E & Annual Report to shareholders
- Immuron Reports Results in SAH Clinical Trial
- Underwritten Public Offer
- Immuron Prices Underwritten Public Offering of ADSs
- Proposed Public Offer of IMRN ADSs
Later from Immuron
- US Defense funds AU$5.5M for Immuron New Gastro Weapon
- Immuron North American Q1 Sales Up 111% YoY
- Immuron Receives AUD $0.53M R&D Tax Concession Refund
- Immuron Plans IMM-124E Trial to Prevent Travelers Diarrhea
- North American Travelan sales up 98% to Dec 2019
Follow Immuron into a list and get an email when it puts out news.
Follow Immuron